

***The Liver Meeting® 2026***  
***Abstract Categories and Descriptors***

- **Acute Liver Failure and Artificial Liver Support**
  - Acute Liver Failure and Artificial Liver Support
- **Acute on Chronic Liver Failure**
  - Acute on Chronic Liver Failure
- **Advanced Practice Providers (NP, PA, RN, PharmD, etc.)**
  - Behavioral and Quality Issues
  - Practice Issues
- **Alcohol-Associated Liver Diseases: Clinical and Experimental**
  - Alcohol-Associated Liver Diseases: Clinical and Experimental
- **Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis**
  - Cholangiocyte Biology
  - Experimental Cholestasis
  - Transport, Bilirubin, Cholesterol, Lipids, and Bile Salts
- **Cell and Molecular Biology**
  - Cell Structure and Function
- **Genomics and Precision Medicine**
  - Genomics and Precision Medicine
- **Gut Liver Axis and Microbiome**
  - Gut Liver Axis and Microbiome
- **Health Disparities/Health Equity Research**
  - Social Determinants of Health
  - Special Populations

- **Health Services and Public Health Research**
  - Cost-Effectiveness and Economics of Care
  - Health Care Delivery/Access/Quality
  
- **Hepatitis - Other Infections**
  - Hepatitis – Other Infections
  
- **Hepatitis B**
  - Diagnostics and Biomarkers – Hep B
  - Epidemiology, Prevention, Natural History – Hep B
  - Therapeutics: Approved Agents – Hep B
  - Therapeutics: New Agents – Hep B
  - Virology, Pathogenesis, and Immunology – Hep B
  
- **Hepatitis C**
  - Diagnostics and Biomarkers – Hep C
  - Epidemiology, Prevention, Natural History
  - Therapeutics: Approved and New Agents
  - Virology, Pathogenesis, and Immunology
  
- **Hepatobiliary Neoplasia**
  - Clinical: Hepatocellular Carcinoma and Cholangiocarcinoma
  - Diagnostics and Liver Imaging
  - Experimental Hepatocarcinogenesis
  
- **Hepatotoxicity**
  - Drug Metabolism, Toxicity, and Therapeutics
  - Pathogenesis and Mechanisms
  - Predictors of Drug Toxicity
  
- **Human Cholestatic and Autoimmune Liver Diseases**
  - Autoimmune Liver Disease
  - PBC/PSC and Other Cholestatic Disease

- **Inflammation and Immunobiology**
  - Adaptive Immunity
  - Animal Models
  - Innate Immunity
  - Mechanisms of Injury
  
- **Liver Fibrogenesis and Non-Parenchymal Cell Biology**
  - Basic Fibrosis Research and Stellate Cell Biology
  - Clinical and Translational Fibrosis Research
  - Imaging and Noninvasive Markers of Liver Disease
  - Kupffer Cell Biology
  
- **Liver Transplantation and Liver Surgery**
  - Cellular Immunobiology, Preservation, and Cell Transplantation
  - Donor and Allocation Issues, Living Donor and Split Liver Transplantation, and Hepatobiliary Surgery
  - Immunosuppression, Outcomes, and Complications
  - Prevention and Treatment of Recurrent Disease
  
- **MASLD and MASH**
  - Diagnostics and Biomarkers – MASH
  - Epidemiology and Natural History, Prevention, and Outcomes
  - Experimental: Basic
  - Experimental: Clinical
  - Therapeutics: Approved/available agents
  - Therapeutics: New Agents
  - Treatment: Non-pharmacologic
  
- **Metabolic and Genetic Disease**
  - Hemochromatosis, Wilson Disease, and  $\alpha$ -1 Antitrypsin Deficiency

- **Pediatric Hepatology**
  - Biliary Atresia and Neonatal Cholestasis
  - Metabolic and Genetic Diseases
  - Pediatric Liver Disease – Basic Science
  - Pediatric Liver Transplantation
  - Viral and Autoimmune Liver Disease
  - Portal Hypertension and Other Complications of Cirrhosis
  - Ascites, Renal Dysfunction, and Hepatorenal Syndrome
  
- **Portal Hypertension and Other Complications of Cirrhosis**
  - Encephalopathy, Infections, and Other Complications
  - Experimental
  - Varices and Bleeding
  
- **Vascular Liver Disease, Hemostasis, and Thrombosis**
  - Hemostasis and Thrombosis
  - Liver Sinusoidal Endothelial Cells
  - Vascular Liver Disease